Kailera Therapeutics Raises $600 million Series B

Company profile · Healthcare & Life Sciences · Updated Recent

Kailera Therapeutics has raised $600M in Series B funding led by Foresite Capital, with participation from Foresite Capital, General Atlantic. Advance KAI-9531 clinical trials for obesity. The funds will be used to Advance KAI-9531 clinical trials for obesity.

Series B$600 millionTotal tracked $600 millionSan Diego, CA

What it does

Next-gen obesity treatment beyond GLP-1

Traction

Kailera Therapeutics is continuing to scale after securing $600M in Series B funding led by Foresite Capital, with participation from Foresite Capital, General Atlantic.

Trend impact

MD-grade thesis held: available source material is not specific enough to support a non-generic investor-economist read without overclaiming.

Funding history

Recent · Series B · $600 million · Foresite Capital

Products & services

Healthcare & Life Sciences workflow monitoring tied to the funding announcement
Customer-facing product described on the company website
Operational tooling for healthcare & life sciences teams
Data capture and reporting across core business processes
Team expansion support funded by the latest round

Open Kailera Therapeutics in the interactive Capvizr dashboard →